Petosemtamab Combo Hits 28.2-Month Median OS in First-Line Head and Neck Cancer
GMAB sits 92% above its 52-week low of $23.62 on elevated volume (4.0× avg).
Summary
Updated Phase 2 data show petosemtamab plus pembrolizumab delivered a median overall survival of 28.2 months in first-line recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma, with a 63% response rate and 19% complete responses in 43 efficacy-evaluable patients. That compares with roughly 10-12 months of median OS cited for recurrent/metastatic HNSCC, so the survival figure is the headline number clinicians will focus on. Median PFS was 9.0 months and 55% of responders held their response at 24 months; safety looked manageable, with no Grade 5 events or treatment-related deaths. The data land at ESMO 2026 and come days after the Rina-S Phase 3 RAINFOL-02 win, keeping Genmab's pipeline news flow strong. The real test is the Phase 3 LiGeR-HN1 trial in the same first-line setting. Genmab hosts an investor update on October 28 at 12:00 p.m. EDT.
At the time of this announcement, GMAB was trading at $45.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6B. The 52-week trading range was $23.62 to $44.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.